Sonoma Pharmaceuticals Enters Material Definitive Agreement

Ticker: SNOA · Form: 8-K · Filed: Oct 22, 2024 · CIK: 1367083

Sentiment: neutral

Topics: material-agreement, corporate-event

TL;DR

Sonoma Pharma just signed a big deal, filing an 8-K. Big news incoming.

AI Summary

Sonoma Pharmaceuticals, Inc. announced on October 17, 2024, that it entered into a material definitive agreement. The company, formerly known as Oculus Innovative Sciences, Inc., is incorporated in Delaware and headquartered in Boulder, Colorado. This filing is a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

This filing indicates a significant new development for Sonoma Pharmaceuticals, potentially impacting its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities, the nature and impact of which are not yet fully detailed in this initial filing.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Sonoma Pharmaceuticals?

The filing states that Sonoma Pharmaceuticals, Inc. entered into a material definitive agreement on October 17, 2024, but the specific details of this agreement are not provided in this initial 8-K filing.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on October 17, 2024.

What was Sonoma Pharmaceuticals, Inc. previously known as?

Sonoma Pharmaceuticals, Inc. was formerly known as Oculus Innovative Sciences, Inc.

Where are Sonoma Pharmaceuticals, Inc.'s principal executive offices located?

Sonoma Pharmaceuticals, Inc.'s principal executive offices are located at 5445 Conestoga Court, Suite 150, Boulder, CO 80301.

Under which section of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

Filing Stats: 960 words · 4 min read · ~3 pages · Grade level 12.3 · Accepted 2024-10-22 08:30:10

Filing Documents

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. As previously reported, effective August 19, 2024, we entered into a distribution agreement (the "Agreement") with Medline Industries, LP ("Medline"), for the marketing and distribution of our wound care products in the United States. The Agreement is for an initial term of five years, On October 17, 2024, we entered into Amendment No. 1 to the Distribution Agreement (the "Amendment"), which allows Medline to also sell our wound care products in Canada, as well as to sell additional over-the-counter wound care products to retailers in both countries. The foregoing description of the Amendment and the Agreement is not complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K, and the Agreement, a redacted copy of which was filed as Exhibit 10.1 to our Current Report on Form 8-K on August 21, 2024.

01

Item 8.01 Other Events. Attached is the updated investor presentation of Sonoma Pharmaceuticals, Inc. and its affiliates (the "Company"). The presentation materials are filed hereto as Exhibit 99.1. Except for historical information herein, matters set forth in this report are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of the Company. These forward-looking statements are identified by the use of words such as "will," "develop," "project," "expect," and "expand," among others. Forward-looking statements in this report are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 10.1 * Amendment No. 1 to Distribution Agreement, dated October 17, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP. 10.2 * Distribution Agreement, dated August 19, 2024, by and between Sonoma Pharmaceuticals, Inc. and Medline Industries, LP (included as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on August 21, 2024, and incorporated herein by reference). 99.1 Investor Presentation as of October 22, 2024. 104 Cover Page Interactive Data File (formatted in Inline XBRL in Exhibit 101). ___________________ Certain portions of the agreement have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to the SEC upon request. * Some exhibits or schedules to the agreement have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish copies of any such schedule or exhibit to the SEC upon request. 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SONOMA PHARMACEUTICALS, INC. Date: October 22, 2024 By: /s/ Amy Trombly Name: Title: Amy Trombly Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing